Obesity is a chronic disease that often requires individualized treatment rather than a one-size-fits-all approach
Our peer-reviewed JMIR study of the GLP-1RA-supported programme reported an average weight loss of 19.1% at 12 months among active subscribers, with 77.7% achieving at least 10% weight loss
Our approachthe Blue Horizon Methodalways starts with a clinical foundation
Estrogen decline during menopause affects virtually every aspect of metabolism, from how calories are burned to where fat gets stored on the body
MECHANISM OF THE WEIGHT LOSS EFFECT OF GLP-1 RECEPTOR AGONISTS GLP-1 RAs potentiate glucose-induced insulinotropic action
The studys investigator, Henning Bliddal, MD, is intrigued by whether or not theres a specific action of GLP-1 receptor agonists on the joint, not through weight loss but by itself. In addition to pain and weight reduction, those studied also had improved WOMAC physical function scores from baseline